Our method shows its potential therapeutic use in CD through acting on multiple targets HSP90AA1 and FPR1, affecting multiple pathways NOD-like receptor signaling pathway and staphylococcus aureus infection pathway, and further affecting multiple CD mechanism genes IL6, TNF, NLRP3, NOD2, FPR2 and IL10. This evidence concerns the gene NLRP3 and staphylococcus aureus infection.